COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda
Formycon initiates clinical program for FYB206, a biosimilar candidate for Keytruda, targeting immuno-oncology. Phase I and III trials underway to assess safety, efficacy, and PK equivalence -
-
-
COMMUNIQUÉ DE PRESSE
MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region
Formycon AG partners with MS Pharma for commercializing FYB203, a biosimilar candidate to Eylea in the MENA region, strengthening biosimilar portfolio and local production -
-
-
COMMUNIQUÉ DE PRESSE
Formycon reports on successful operating business and financial figures for the first quarter of 2024
Formycon reports successful Q1 2024 operating business and financial figures, including acquisitions and strategic investments. Revenue at €17.7 million. Invitation to conference call
